One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
about
Polypoidal choroidal vasculopathy: an update on therapeutic approachesProspective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month resultsMacular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.Polypoidal choroidal vasculopathy: an angiographic discussion.Genetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathyClinical features, management and visual outcome of polypoidal choroidal vasculopathy in Indian patients.A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.Three major loci involved in age-related macular degeneration are also associated with polypoidal choroidal vasculopathy.Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short-term resultsPolypoidal choroidal vasculopathy and history of central serous chorioretinopathy.Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatmentOutcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab.Automatic Segmentation of Polypoidal Choroidal Vasculopathy from Indocyanine Green Angiography Using Spatial and Temporal Patterns.Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea.EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathyIntravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathyRanibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysisAflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth FactorShort-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathySerum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degenerationResults of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathyIntravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis.Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy.One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.Investigation of precursor lesions of polypoidal choroidal vasculopathy using contralateral eye findingsLow-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.Photodynamic therapy for polypoidal choroidal vasculopathy secondary to choroidal nevus.Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian populationOne-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.Retinal photodamage by endogenous and xenobiotic agents.Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.Asian age-related macular degeneration phenotyping study: rationale, design and protocol of a prospective cohort study.Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects.The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients.Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup.Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
P2860
Q27006758-2CFEBB3E-9A27-4A03-AE27-DE9769FF27C6Q27311334-F414A6EF-BC53-4901-A2E0-F5AFD48A6304Q31044313-6BF80C0B-12BF-4594-8C74-60EE967B65F9Q33523990-9EF0F23E-B54D-4B4F-ADD3-E7B764951274Q33645265-D74B060A-0336-4BF5-9220-B5AA685A55E0Q33650784-332EECAC-7094-4723-957C-7363CCFAC4E4Q33825750-4A15490D-B5F5-43C6-8150-5A833476BEC4Q33982669-3BCC7986-62C7-47FE-BE49-D9ABB9D2AFEAQ34007126-E8729B6D-E1C0-4448-BCFE-CA5C3F76CEBCQ34055052-E1B7B277-FA9E-4397-84B1-0AFFB57AC983Q34655439-DB63209D-BCD2-4C41-BEE5-1DBD74536940Q34695085-F376A874-4577-4A28-8078-FD4EF14FA72CQ34718477-1A318C80-F3EC-4DC3-AE14-7812B475DF3FQ34958682-2CDEE45C-AC0E-489F-821F-C4BB17AA5942Q35190854-EF28554A-A7B2-41A7-8041-5D570CC1F33BQ35549978-4786DF47-0B0A-470D-B2FC-06AFF899C394Q35550819-08EA13D4-C9D5-422B-B918-FE0826562FAEQ35820349-F5D9B557-15EE-4575-BF63-DBDE58AF6F90Q35838315-745B434C-AA25-43BC-9AF9-E0DEC6D0A877Q35904896-ED9F18BF-622B-42EC-9C18-585D97F895ECQ35999201-E423D442-286E-425A-8D62-D47BF9DC2C32Q36727683-F94F6D95-A6F1-483A-8E1B-489A53F02FC8Q36786002-3B695A4B-4158-4CDB-915B-DB06FF320B8BQ37095502-467EB7E5-B484-476D-9505-E43990CBC9A2Q37168836-C87025EA-3F60-47CC-9898-25D9A09624D3Q37360918-DF538933-2C20-4C03-8BDD-766B0E0369E2Q37554103-86E691B3-318F-40C4-8253-1196548B1FA8Q37617515-8EAE1730-D8F4-4452-8E35-C1F099426D1FQ37638911-D23E1E32-D871-478E-8462-D070CCEBF482Q37653057-BAABF40C-D45A-4DE1-93A0-E896FA5E1D49Q37661641-ABB1FD36-B99D-41D5-969F-147404497D53Q37901282-F88B0F8D-5129-4041-8A09-A09C81BB0E04Q38009850-06740C26-6F27-4CEE-9AC5-2E2BC1853E5CQ38477676-4F03066A-A747-44F8-ABE3-625798B65167Q40019102-6C53C20B-9B92-4316-8FAC-205F221A1C17Q41102960-FFA7FBD2-D329-47D5-8754-86FB4822E8CEQ41529588-7BA00F70-818C-4C11-91DD-C0373209274DQ41627130-2053E655-3D77-44BA-824F-40884A2B5813Q41763938-28762CD2-7C31-4818-8877-640D4A8F0B6CQ41852664-0FE2C82A-E507-4DA5-ACCE-229AB655726F
P2860
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
One-year outcomes of photodyna ...... ulopathy in Japanese patients.
@ast
One-year outcomes of photodyna ...... ulopathy in Japanese patients.
@en
type
label
One-year outcomes of photodyna ...... ulopathy in Japanese patients.
@ast
One-year outcomes of photodyna ...... ulopathy in Japanese patients.
@en
prefLabel
One-year outcomes of photodyna ...... ulopathy in Japanese patients.
@ast
One-year outcomes of photodyna ...... ulopathy in Japanese patients.
@en
P2093
P1433
P1476
One-year outcomes of photodyna ...... culopathy in Japanese patients
@en
P2093
Hirokazu Sakaguchi
Kaori Sayanagi
Masahito Ohji
Yasuo Tano
Yasushi Ikuno
Yusuke Oshima
P304
P356
10.1016/J.OPHTHA.2007.02.031
P50
P577
2007-06-20T00:00:00Z